## **UNITED STATES**

# SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

FORM 8-K

**CURRENT REPORT** 

PURSUANT TO SECTION 13 OR 15(d) OF THE

**SECURITIES EXCHANGE ACT OF 1934** 

Date of report (Date of earliest event reported): May 1, 2007

IMMUNOMEDICS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction 000-12104 (Commission File Number) 61-1009366 (I.R.S. Employer

of Incorporation)

Identification No.)

300 American Road, Morris Plains, New Jersey (Address of Principal Executive Offices) 07950 (Zip Code)

(973) 605-8200

(Registrant s telephone number, including area code)

(Former Name or Former Address, if Changed Since Last Report)

### Edgar Filing: IMMUNOMEDICS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: IMMUNOMEDICS INC - Form 8-K

#### Item 9.01 Financial Statements and Exhibits.

### (d) Exhibits.

Exhibit No. Description

5.1 Opinion of Morgan Lewis & Bockius LLP (for the Company s common stock offering on May 1, 2007, expected to

close May 7, 2007).

## Edgar Filing: IMMUNOMEDICS INC - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMMUNOMEDICS, INC.

By: /s/ Cynthia L. Sullivan Cynthia L. Sullivan President and Chief Executive Officer

Dated: May 1, 2007